NASDAQ : ORIC
ORIC Pharmaceuticals, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 9.24 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 957.75M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 33.77M | 33.19M | 28.82M | 25.61M | 25.09M | 22.01M |
| Research & Development | 122.36M | 109.82M | 114.07M | 85.17M | 61.68M | 56.86M |
| Operating Expenses | 156.14M | 143.00M | 142.90M | 110.78M | 86.77M | 78.87M |
| Operating Income | -156.14M | -143.00M | -142.90M | -110.78M | -86.77M | -78.87M |
| Interest & Investment Income | 15.79M | 13.54M | 15.05M | 10.08M | 2.65M | 141.00K |
| Other Non Operating Income (Expenses) | 15.00K | |||||
| EBT Excluding Unusual Items | -140.35M | -129.47M | -127.85M | -100.70M | -84.12M | -78.72M |
| Pretax Income | -140.35M | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
| Net Income | -140.35M | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
| Net Income to Common | -140.35M | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
| Shares Outstanding (Basic) | 103.87M | 87.79M | 69.73M | 51.45M | 39.66M | 37.95M |
| Shares Outstanding (Diluted) | 103.87M | 87.79M | 69.73M | 51.45M | 39.66M | 37.95M |
| EPS (Basic) | -1.35 | -1.47 | -1.83 | -1.96 | -2.25 | -2.07 |
| EPS (Diluted) | -1.35 | -1.47 | -1.83 | -1.96 | -2.25 | -2.07 |
| Free Cash Flow | -112.26M | -111.68M | -113.85M | -86.54M | -77.22M | -60.48M |
| Free Cash Flow Per Share | -1.08 | -1.27 | -1.63 | -1.68 | -1.95 | -1.59 |
| EBITDA | -155.00M | -141.78M | -141.79M | -109.75M | -85.80M | -77.97M |
| D&A For EBITDA | 1.14M | 1.22M | 1.11M | 1.03M | 966.00K | 897.00K |
| EBIT | -156.14M | -143.00M | -142.90M | -110.78M | -86.77M | -78.87M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 37.48M | 45.67M | 59.41M | 23.38M | 66.84M | 226.01M |
| Short-Term Investments | 227.28M | 235.82M | 196.55M | 184.80M | 139.43M | 10.97M |
| Cash & Short-Term Investments | 264.76M | 281.49M | 255.96M | 208.19M | 206.27M | 236.98M |
| Prepaid Expenses | 8.93M | 6.98M | 6.29M | 4.41M | 4.18M | 3.54M |
| Total Current Assets | 273.69M | 288.47M | 262.25M | 212.60M | 210.46M | 240.52M |
| Property, Plant & Equipment | 2.24M | 9.07M | 11.30M | 12.01M | 14.24M | 14.21M |
| Long-Term Investments | 122.80M | 110.76M | 26.85M | 21.95M | 43.39M | |
| Other Long-Term Assets | 5.95M | 589.00K | 588.00K | 552.00K | 529.00K | 521.00K |
| Total Assets | 404.69M | 408.89M | 274.14M | 252.01M | 247.18M | 298.64M |
| Accounts Payable | 3.87M | 3.82M | 1.55M | 944.00K | 1.32M | 1.89M |
| Accrued Expenses | 13.56M | 13.26M | 20.11M | 16.76M | 11.41M | 11.34M |
| Current Portion of Leases | 3.33M | 3.33M | 3.18M | 2.75M | 2.66M | 1.93M |
| Total Current Liabilities | 20.76M | 20.42M | 24.85M | 20.46M | 15.39M | 15.15M |
| Long-Term Leases | 2.67M | 4.11M | 6.17M | 7.46M | 9.44M | 10.52M |
| Total Liabilities | 23.43M | 24.53M | 31.02M | 27.92M | 24.83M | 25.67M |
| Common Stock | 11.00K | 11.00K | 7.00K | 6.00K | 5.00K | 4.00K |
| Additional Paid-In Capital | 1.15B | 1.08B | 805.51M | 658.75M | 557.87M | 518.18M |
| Retained Earnings | -769.50M | -692.24M | -562.77M | -434.93M | -334.23M | -245.11M |
| Comprehensive Income & Other | -1.02M | 786.00K | 379.00K | 258.00K | -1.29M | -103.00K |
| Total Common Equity | 381.26M | 384.36M | 243.12M | 224.09M | 222.35M | 272.98M |
| Shareholders' Equity | 381.26M | 384.36M | 243.12M | 224.09M | 222.35M | 272.98M |
| Total Liabilities & Equity | 404.69M | 408.89M | 274.14M | 252.01M | 247.18M | 298.64M |
| Total Debt | 6.00M | 7.44M | 9.36M | 10.21M | 12.10M | 12.44M |
| Net Cash (Debt) | 258.76M | 274.05M | 246.60M | 197.97M | 194.17M | 224.54M |
| Net Cash Per Share | 2.49 | 3.12 | 3.54 | 3.85 | 4.90 | 5.92 |
| Filing Date Shares Outstanding | 103.65M | 100.36M | 71.03M | 67.38M | 45.09M | 39.43M |
| Total Common Shares Outstanding | 103.64M | 98.53M | 71.02M | 54.87M | 45.09M | 39.43M |
| Working Capital | 252.94M | 268.05M | 237.40M | 192.14M | 195.07M | 225.37M |
| Book Value Per Share | 3.68 | 3.90 | 3.42 | 4.08 | 4.93 | 6.92 |
| Tangible Book Value | 381.26M | 384.36M | 243.12M | 224.09M | 222.35M | 272.98M |
| Tangible Book Value Per Share | 3.68 | 3.90 | 3.42 | 4.08 | 4.93 | 6.92 |
| Machinery | 8.35M | 8.00M | 8.36M | 7.39M | 7.07M | 5.69M |
| Leasehold Improvements | 2.07M | 2.06M | 2.04M | 1.97M | 1.98M | 1.71M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -140.35M | -129.47M | -127.85M | -100.70M | -89.12M | -78.72M |
| Depreciation & Amortization | 1.14M | 1.22M | 1.11M | 1.03M | 966.00K | 897.00K |
| Loss (Gain) From Sale of Assets | 22.00K | 40.00K | 2.00K | |||
| Loss (Gain) From Sale of Investments | -374.00K | -2.30M | -8.10M | -6.17M | -1.04M | 1.35M |
| Stock-Based Compensation | 25.90M | 25.04M | 20.21M | 15.23M | 14.46M | 12.85M |
| Change in Accounts Payable | -189.00K | -7.25M | 1.82M | 3.28M | -1.48M | 2.93M |
| Change in Other Net Operating Assets | 2.24M | 1.79M | 143.00K | 1.62M | 1.03M | 1.14M |
| Operating Cash Flow | -111.64M | -110.97M | -112.66M | -85.69M | -75.14M | -59.54M |
| Capital Expenditures | -620.00K | -712.00K | -1.19M | -849.00K | -2.08M | -939.00K |
| Investment in Securities | -99.04M | -147.32M | 23.32M | -42.55M | -107.17M | 159.37M |
| Investing Cash Flow | -99.66M | -148.03M | 22.14M | -43.40M | -109.25M | 158.44M |
| Issuance of Common Stock | 175.65M | 247.66M | 126.72M | 85.89M | 25.62M | 50.99M |
| Other Financing Activities | -2.73M | -2.40M | -168.00K | -227.00K | -399.00K | -1.85M |
| Financing Cash Flow | 172.92M | 245.26M | 126.55M | 85.66M | 25.23M | 49.13M |
| Net Cash Flow | -38.38M | -13.74M | 36.02M | -43.43M | -159.17M | 148.03M |
| Free Cash Flow | -112.26M | -111.68M | -113.85M | -86.54M | -77.22M | -60.48M |
| Free Cash Flow Per Share | -1.08 | -1.27 | -1.63 | -1.68 | -1.95 | -1.59 |
| Levered Free Cash Flow | -68.83M | -69.10M | -67.10M | -49.08M | -42.02M | -32.71M |
| Unlevered Free Cash Flow | -68.83M | -69.10M | -67.10M | -49.08M | -42.02M | -32.71M |
| Change in Working Capital | 2.05M | -5.46M | 1.97M | 4.90M | -445.00K | 4.07M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 957.75M | 796.64M | 569.48M | 501.88M | 264.77M | 578.91M |
| Enterprise Value | 698.99M | 516.90M | 307.06M | 285.29M | 83.64M | 301.93M |
| Last Close Price | 9.24 | 8.18 | 8.07 | 9.20 | 5.89 | 14.70 |
| PB Ratio | 2.51 | 2.07 | 2.34 | 2.24 | 1.19 | 2.12 |
| P/TBV Ratio | 2.51 | 2.07 | 2.34 | 2.24 | 1.19 | 2.12 |
| Debt / Equity Ratio | 0.02 | 0.02 | 0.04 | 0.05 | 0.05 | 0.05 |
| Net Debt / Equity Ratio | -0.68 | -0.71 | -1.01 | -0.88 | -0.87 | -0.82 |
| Net Debt / EBITDA Ratio | 1.67 | 1.93 | 1.74 | 1.80 | 2.26 | 2.88 |
| Net Debt / FCF Ratio | 2.31 | 2.45 | 2.17 | 2.29 | 2.52 | 3.71 |
| Quick Ratio | 12.76 | 13.79 | 10.30 | 10.18 | 13.40 | 15.64 |
| Current Ratio | 13.19 | 14.13 | 10.55 | 10.39 | 13.68 | 15.88 |
| Return on Equity (ROE) | -39.80% | -41.27% | -54.73% | -45.11% | -35.98% | -27.98% |
| Return on Assets (ROA) | -25.97% | -26.17% | -33.95% | -27.74% | -19.87% | -16.50% |
| Return on Capital Employed (ROCE) | -40.70% | -36.80% | -57.30% | -47.80% | -37.40% | -27.80% |
| Earnings Yield | -14.62% | -16.25% | -22.45% | -20.06% | -33.66% | -13.60% |
| FCF Yield | -11.72% | -14.02% | -19.99% | -17.24% | -29.17% | -10.45% |
| Buyback Yield / Dilution | -43.06% | -25.91% | -35.52% | -29.74% | -4.48% | -72.97% |